A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Part of paid clinical trials in Anaheim, California.
- Sponsor
- Incyte Corporation
- Study ID
- NCT02763319
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab (RTX) — DRUGRituximab: Dose: 375 mg/m2 IV
- Tafasitamab — DRUGTafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
- Bendamustine (BEN) — DRUG
Study Details
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Key Dates
- Start date
- Nov 28, 2016
- Status verified
- Jul 2025
- Primary completion
- Jun 21, 2024
- Completion
- Jun 21, 2024
Study Design
- Enrollment
- 453 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tafasitamab and bendamustineTafasitamab and bendamustine
- Active Comparator: Rituximab and bendamustineRituximab and bendamustine
Primary Outcome Measure
Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population [ Time Frame: up to 41.4 months ]
Locations (18)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MorphoSys Research Site | Anaheim | California | 92801 | - |
| MorphoSys Research Site | Bakersfield | California | 93309 | - |
| Morphosys Research Site | Burbank | California | 91505 | - |
| Morphosys Research Site | Fresno | California | 93701 | - |
| MorphoSys Research Site | Los Angeles | California | 90017 | - |
| MorphoSys Research Site | Whittier | California | 90603 | - |
| MorphoSys Research Site | Plainville | Connecticut | 06062 | - |
| MorphoSys Research Site | Skokie | Illinois | 60077 | - |
| MorphoSys Research Site | Detroit | Michigan | 48202 | - |
| MorphoSys Research Site | Rochester | Minnesota | 55905 | - |
| MorphoSys Research Site | Hattiesburg | Mississippi | 39401 | - |
| Morphosys Research site | Jackson | Mississippi | 39126 | - |
| Morphosys Research Site | Morristown | New Jersey | 07960 | - |
| MorphoSys Research Site | New York | New York | 10029 | - |
| MorphoSys Research Site | Stony Brook | New York | 11794 | - |
| MorphoSys Research Site | Oklahoma City | Oklahoma | 73142-2015 | - |
| MorphoSys Research Site | Knoxville | Tennessee | 37909 | - |
| Morphosys Research Site | Lubbock | Texas | 79415 | - |
Find similar trials in Anaheim, CA
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaEARLY_PHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)PHASE2/PHASE3 · Recruiting · Merck Sharp & Dohme LLC · Glendale, Arizona